Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 1998

View Archived Issues

Dornier's BPH device approved by FDA

Biomira updates shareholders at annual general meeting

Aastrom Biosciences receives SBIR grant for dendritic cell expansion technology research

Argonex raises funds for cancer vaccine programs

Dura and Spiros provide development update on asthma products

Urinary reflux product enters phase III

Genome Therapeutics reaches milestone in Schering-Plough alliance

Initiation of late-stage Avicine clinical trial

Access and Block Drug sign agreement for international rights to amlexanox

Molecules to Market changes name

Sertoli Technologies issued second U.S. patent for Sertoli-based cell therapies

Hemosol advances blood substitute in clinical studies for several indications

Procept's PRO-2000 gel protects against herpes infection in mice

Flavopiridol induces apoptosis, regression of human hematological malignancies

17beta-HSD type 1 inhibitors: a new treatment option for hormone-dependent breast cancer

Abbott and Boehringer Ingelheim sign comarketing agreement

PNU-151774E, a safe and effective anticonvulsant in preclinical testing

Procter & Gamble R&D on metalloprotease inhibition

Perimidine-based CRF antagonists developed at Agouron

BMS prepares novel sulfenamide taxane derivatives

Byk Gulden patents another series of thiazole PDE IV inhibitors

Antitumor, antifungal cryptophycins developed by U.S. pharmaceutical/academic team

Lactadherin protects against symptomatic rotavirus infection in infants

No-approval recommendation given for AD-32 by FDA advisory committee

Large U.S. trial confirms high efficacy rate of mifepristone + misoprostol in early pregnancy

Rebetron now available in the U.S.

U.K. launch of Zoladex for assisted conception

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...